Michael Gelband’s Fortress Biotech FBIO Stock Holding History

Michael Gelband’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,932	Closed	-$39K	–	2083
2022 Q1	$39K	Buy	1,932 +1,082	+127%	+$29.6K	﹤0.01%	2080
2021 Q4	$32K	Buy	850 +31	+4%	+$1.38K	﹤0.01%	2063
2021 Q3	$40K	Buy	819 +7	+0.9%	+$342	﹤0.01%	1987
2021 Q2	$43K	Buy	+812	New	+$49K	﹤0.01%	2234
2020 Q2	–	Sell	-1,553	Closed	-$44K	–	1843
2020 Q1	$44K	Sell	1,553 -4,094	-72%	-$136K	﹤0.01%	966
2019 Q4	$218K	Buy	+5,647	New	+$145K	﹤0.01%	1306

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Michael Gelband's FBIO Position: Q2 2022 in Review

Michael Gelband sold out of Fortress Biotech (FBIO) in Q2 2022, closing a stake of 1,932 shares — an estimated $39K sold.

Michael Gelband first reported a position in FBIO in Q4 2019 and held it in 6 quarters. The position peaked at $218K in Q4 2019. 66 funds tracked by Wall St. Rank hold FBIO as of Q2 2022.

Michael Gelband reported no remaining Fortress Biotech position as of Q2 2022 after selling out during the quarter.
Michael Gelband sold 1,932 Fortress Biotech shares in Q2 2022, an estimated $39K.
Michael Gelband first reported a position in Fortress Biotech in Q4 2019 and held it in 6 quarters.
Michael Gelband's Fortress Biotech position peaked at $218K in Q4 2019.
66 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.